Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice call !! someone sell me your 6's
PDPR Technical Analysis ??? that to funny.
pleas explain why you keep posting the news released by pdpr yesterday... there are no contracts, no mention of future money from it and the shares did not move yesterday...there was more selling than buying... only 10k shares of buying and 3 million shares sold..lmao !
no one painted the tape at EOD on MCIG.. more debunked claims..lol
mcig still green...
Manipulation? that is HILARIOUS..
PDPR's HOD was put in this am with all the selling ...
market likes it? PDPR all sells but 1 buy to paint the tape...
im confused why everyone keeps posting PDPR news OVER and OVER...lmao..
MCIG getting closer to the .21 mark and is still trending up...
FINALLY news form this company after 3 years and it's a fluff story.. cant wait to see the fins from this supposed venture..lmao
oops and the stock drops..lmao
PDPR news out after 3 years and not one share has been bought yet
LMAO ... MCIG has moved almost 6 1/2 cents in a week... still looks like buyers are buying MCIG..
MCIG moving up from .141 low getting close to the .21's and beyond !!
this company has gone no where in over 3 years with zero news except for the stop sign being removed....
all pdpr does is post dumb stuff that gets ZERO likes on their social media...
Still waiting for something showing PDPDR knows what they are doing...
btw- FYI SEO is so out dated and so 10 years ago...
Nice DD on MM's
i say take them out and laugh all the way to the bank when it jumps !!
NEWS out
American CryoStem to file Investigational New Drug Application with FDA
EATONTOWN, NJ / ACCESSWIRE / December 13, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has completed its Pre-IND discussions with the FDA concerning its ongoing work to file an Investigational New Drug Application (IND) titled:''Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Chronic Post Concussive Syndrome (CCS) in Retired Athletes and Retired US Military Servicemen'' utilizing its fully patented collect-process-store-return to point of care platform.
The planned application filing is a major milestone for the Company. CRYO has developed an autologous adipose tissue derived stem cell product ATCELLâ„¢ which will be used for the proposed Phase 1 Safety Study to treat the long term effects of repetitive traumatic brain injuries. The US Centers for Disease Control and Prevention (CDC) defines traumatic brain injury (TBI) as a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury.
Post-concussion syndrome is a complex disorder in which various symptoms such as headaches and dizziness last for weeks and sometimes months after the injury that caused the concussion. In approximately 15% of people, symptoms may persist for years or be permanent. If symptoms are not resolved by one year, they are likely to be permanent, though improvements may occur after even two or three years or may suddenly occur after a long time without much improvement.
Traumatic Brain Injury is a major cause of mortality in the United States, contributing to approximately 30% of all injury-related deaths. The burden on the health care system is also substantial; in 2010, approximately 2.5 million emergency department (ED) visits, hospitalizations, or deaths were associated with TBI. From 2001 to 2010, the rates of ED visits increased by 70%, and rates of hospitalization and death increased by 11% and 7%, respectively.
The direct and indirect costs of traumatic brain injury in the U.S. have been estimated to be $48.3 billion annually. Lifetime costs for one person surviving a severe TBI can reach $4 million. An estimate of medical and non-medical per TBI survivor averages $151,587. Average costs rise dramatically for those individuals who undergo rehabilitation. In one study, after a 4-year follow-up, average costs for medical and long-term care services averaged $196,460 for survivors receiving rehabilitation services compared to $17,893 for those receiving no rehabilitation. (http://www.aboutbraininjury.org/financial-costs-of-brain-injuries/)
Recent estimates suggest that between 250,000 - 500,000 of the 2.5 million U.S. military service members deployed to Iraq and Afghanistan may be affected by TBI. The estimated costs of treatment, just for blast-related TBI in the U.S., is $2.5 billion annually. Additionally, the estimated percentage of athletes that suffer from mild cognitive impairment (MCI) due to repetitive sub-concussive or concussive brain injuries varies widely.
The Company, in preparation for this application has invested significant resources and upgraded its laboratory facility from an FDA registered tissue bank to become a biologic drug manufacturer. To accomplish this, the Company has acquired addition laboratory and clean room space, completed the installation and certification of additional equipment, upgraded air handling and filtration systems, implemented a cGMP process conversion, and product and process validations to support the production of its ATCELLâ„¢ product to be used in this planned IND filing.
Anthony Dudzinski, COO commented ''ATCELLâ„¢ is a autologous adipose tissue derived stem cell product with cellular biomarker identification through flow cytometry consistently in excess of 97%, each ATCELLâ„¢ product is genetically matched to the treated patient.'' He continued, ''The Company believes using genetically matched cells with high cellular purity and consistency for unmet medical needs such as Chronic Concussive Syndrome supports the Company's ongoing efforts to achieve regulatory approvals for its patented ATCELLâ„¢ product for a wide range of uses domestically and through its licensed affiliates in China, Japan, Hong Kong and Thailand.''
Upon acceptance of the filing by FDA and initiation of the clinical trial the Company intends to make its ATCELLâ„¢ product available for clinical study by collaborators and partners that wish to develop additional treatment protocols that have shown early promise in the treatment of neurological disorders, orthopaedic applications and tissue repair among others to rapidly expand approved uses of its ATCELLâ„¢ products in the global cellular therapy markets.
For further detailed Corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or
phone 732-747-1007
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
SOURCE: American CryoStem Corporation
© Copyright 2018 ACCESSWIRE. All Rights Reserved.
I too look forward to any of your updates !!
thank you in advance
looks like something may be brewing .... crossing fingers !!
nice up day so far w/ nice volume !!
wow, huge volume.. imo- someone is loading up...
goodibag,
why is this news story not on tocmarkets? just curious ...
Thomas Hemingway was on the S1 filed on 6/23/2009 fofu page 24 https://www.sec.gov/Archives/edgar/data/1182011/000120095209000267/ffi_s1a-90623.htm the stock went public at 5.00 and dropped like rock till June 2014 when it was taken over by CAFS and now he is back running it again...hmmm... please look back at his track record with the other stocks he was involved in on his bio in the current 8k.. Notice it does NOT mention anything about him being the Chairman and Former President, Chief Executive Officer and Chief Financial Officer of FOFU on his Bio as it does in the above S1 page 29 filed back on 6/23/2009...
here is some DD you might find very interesting.... Thomas Hemingway was on the S1 filed on 6/23/2009 fofu page 24 https://www.sec.gov/Archives/edgar/data/1182011/000120095209000267/ffi_s1a-90623.htm the stock went public at 5.00 and dropped like rock till June 2014 when it was taken over by CAFS and now he is back running it again...hmmm... please look back at his track record with the other stocks he was involved in on his bio in the current 8k.. Notice it does NOT mention anything about him being the Chairman and Former President, Chief Executive Officer and Chief Financial Officer of FOFU on his Bio as it does in the above S1 page 29 filed back on 6/23/2009...
my bad, it was not you..
nice... btw- where did i state i hate this stock?? lmao...
what is the former CFO first name that you chatted with??
hemingway has ZERO part of CAFS ...and hasnt had anything to do with cafs since june 2014
im sure you are up !!
Guess you are WRONG Mciggy... Mcig looking good so far today...
the shell was sold back in mid 2014...
not to be rude but nothing states the company is related to any of your posts... even Nevada link doesn't show any owners, it only shows it's Reinstatement..
hemmingway has not been a part of the shell since it was fofu back in mid 2014 when it was taken over by Cafe...
please post where it states new management and what is the vertical market moving forward?
Ty Les for the GREAT information on MCIG !!
PLEASE explain the reason for your thoughts why you think a merger w/ ITNF another dark none reporting shell???
i agree with you !!